Every material Form 8-K Sight Sciences, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sight Sciences reported third-quarter 2026 revenue of $24.9 million, up 25% from a year earlier, and raised its full-year 2026 revenue guidance to $92 million to $93 million from $88 million to $92 million. Its net loss narrowed to $6.8 million from $8.2 million, and cash used in operations fell 74%, though its adjusted operating expense guidance was maintained. The guidance increase and narrower loss point to improving results for shareholders.
Q3 2026 revenue of $24.9 million, up 25% from $19.9 million in Q3 2025; Interventional Dry Eye revenue reached $3.9 million versus $0.2 million a year earlier
Full-year 2026 revenue guidance raised to $92 million to $93 million; Interventional Dry Eye guidance raised to approximately $12 million from $9 million to $11 million
Net loss of $6.8 million, or $0.12 per share, compared with $8.2 million, or $0.16 per share, in Q3 2025
Cash and cash equivalents of $77.4 million as of September 30, 2026; full-year adjusted operating expense guidance held at $92 million to $94 million
Sight Sciences appointed Kashif Rashid, a former general counsel at Nevro Corp., as Chief Legal Officer and Corporate Secretary effective August 10, 2026. Jeremy Hayden leaves the same roles on that date and stays with the company through August 31, 2026 to help with the transition. For shareholders, the filing discloses the pay terms for the new officer and the severance terms for the departing one.
Rashid's initial base salary is $450,000, with an annual cash bonus target of 50% of base salary.
Rashid is eligible for a restricted stock unit award valued at $1,400,000, vesting in four equal annual installments starting August 10, 2027.
Hayden's separation is contingent on a separation agreement and release; it provides one year of base salary and up to one year of COBRA benefits.
Rashid previously served as General Counsel of Nevro Corp. from December 2017 to January 2024.
Sight Sciences reported second-quarter 2026 revenue of $23.4 million, up 20% from a year earlier, and raised its full-year 2026 revenue guidance to $88 million to $92 million. The company also lowered its adjusted operating expense guidance to $92 million to $94 million, and its net loss narrowed to $4.4 million from $11.9 million a year earlier.
Q2 2026 revenue was $23.4 million, up 20% from $19.6 million in Q2 2025.
2026 revenue guidance raised to $88 million to $92 million, from $83 million to $89 million.
2026 adjusted operating expense guidance lowered to $92 million to $94 million, from $93 million to $96 million.
Net loss was $4.4 million, or $0.08 per share, versus $11.9 million, or $0.23 per share, in Q2 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sight Sciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →